Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
CAR-T cells engineered to attack two leukemia proteins show promise in preclinical tests
CAR-T cells engineered to attack two leukemia proteins show promise in preclinical tests
Read also
Takeda
Takeda walks away from cell therapy in priority U-turn
Taysha Says
Taysha Says FDA Grants Breakthrough Therapy Designation To In Rett Syndrome
Intravitreal Injection of Retinal Progenitor
Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy
Mercury Bio
Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein
